Skip to Content

Emmaus Life Sciences Inc EMMA

Morningstar Rating
$0.07 0.00 (0.00%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

EMMA is trading at a 318% premium.
Price
$0.07
Fair Value
$6.54
Uncertainty
Extreme
1-Star Price
$4.33
5-Star Price
$3.50
Economic Moat
Spc
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if EMMA is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$0.07
Day Range
$0.070.07
52-Week Range
$0.050.28
Bid/Ask
$0.00 / $0.16
Market Cap
$4.41 Mil
Volume/Avg
1,486 / 15,108

Key Statistics

Price/Earnings (Normalized)
Price/Sales
0.13
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Emmaus Life Sciences Inc is a biopharmaceutical company engaged in the discovery, development, and commercialization of new treatments and therapies predominantly for rare and orphan diseases. The company's commercial product is Endari, an oral pharmaceutical grade L-glutamine treatment indicated to reduce acute complications of sickle cell disease in adult and pediatric patients five years of age and older. Its products in the pipeline include Diverticulosis and Cell Sheet Engineering.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Core
Total Number of Employees
55

Valuation

Metric
EMMA
Price/Earnings (Normalized)
Price/Book Value
Price/Sales
0.13
Price/Cash Flow
3.40
Price/Earnings
EMMA

Financial Strength

Metric
EMMA
Quick Ratio
0.13
Current Ratio
0.19
Interest Coverage
0.39
Quick Ratio
EMMA

Profitability

Metric
EMMA
Return on Assets (Normalized)
−7.42%
Return on Equity (Normalized)
Return on Invested Capital (Normalized)
Return on Assets
EMMA
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Novo Nordisk A/S ADR
NVO
YdckjysfRsyzv$579.2 Bil
Vertex Pharmaceuticals Inc
VRTX
TwmlxfjcsXcwjr$126.0 Bil
Regeneron Pharmaceuticals Inc
REGN
SdhrhbvQpzjhg$117.6 Bil
Moderna Inc
MRNA
GnllhjdxKkr$46.5 Bil
Alnylam Pharmaceuticals Inc
ALNY
RlcmrhdscMswwchh$29.9 Bil
argenx SE ADR
ARGX
XkxfhlfqTphvd$27.7 Bil
BioNTech SE ADR
BNTX
XtsqxbgpLlhs$20.8 Bil
Biomarin Pharmaceutical Inc
BMRN
NtvhsgndBslqsj$15.8 Bil
United Therapeutics Corp
UTHR
TskfqfhHnsv$14.6 Bil
Incyte Corp
INCY
YpkgtgvWxtpr$12.9 Bil

Sponsor Center